Forgot your password?
New user?
Nanoparticle fear over anti-odour socks
Fragment-based Lead Discovery Conference 2008
test conference
Document Actions
Discovery & Selection of Successful Drug Candidates with Special Emphasis on Structure-Based Drug Design
| Type | Conference |
|---|---|
| Language | English |
| Date |
April 26, 2009
to April 29, 2009 |
| Venue |
The Cambridge Hyatt | Boston, MA , |
| Chemistry Specialties |
|
| Chemistry Techniques |
|
| Contact |
ACS ProSpectives , US acsprospectives@acs.org |
| Add event to calendar |
vCal (Windows, Linux)
iCal (Mac OS X)
|
by
Admin
—
last modified
04-17-09 10:00 PM
In an effort to add value to an already very successful conference, we have expanded the structure-based drug design session of the 5th annual “Discovery & Selection of Successful Drug Candidates” conference to a full day. Chairs Andrew Combs of Incyte, and Greg Roth of The Burnham Institute for Medical Research, are joined this year by co-chair Scott Kuduk of Merck, as well as Vinod Patel of Amgen and Guy Bemis of Vertex, who developed the structure-based drug design portion of this program. Together, they have gathered another group of highly-regarded pharmaceutical industry scientists, who will lecture and collectively present about 20 case studies over the course of the symposia.
Speakers
Structure Based Drug Design
* Keynote: Peter Mueller of Vertex
* Mike Palmer of Pfizer (UK) on PDE5
* Matt Weiss of Amgen on BACE Inhibitors
* Graham Johnson of RibX on Radezolid
* Vadim Dudkin of Merck
* Christopher Smith, Lilly San Diego on SGX523
* Christopher J. Helal of Pfizer on PDE10A Inhibitors
ADME – CNS Blood Brian Barrier Permeability
* Marlon Cowart of Abbott on H3 antagonists
* Mark Layton of Merck on NR2B antagonists
* Chris Shaffer of Pfizer on Neuropharmacokinetic Relationships
* Richard Hartz of BMS on CRF antagonists
PK/PD- Successful Transitions to the Clinic
* Gerald Miwa, recently retired from Millennium
* Greg Vite of BMS
* Robert Marquis of GSK
* Ronnie Palin of Schering Plough
Prospectives from Industry Leaders
* Alan Palkowitz of Eli Lilly
* Scott Biller of Novartis
* William Greenlee of Schering Plough
* Terence Kelly of Boehringer Ingelheim